Opportunities to significantly reduce expenditure associated with cancer drugs

ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe

(2016) N. Cherny et al.   ANNALS OF ONCOLOGY

Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study

(2016) Sabine Vogler et al.   LANCET ONCOLOGY

The drug industry can help reduce cancer drug costs

(2016) Peter J Gilbar et al.   BMJ-British Medical Journal

Overspending driven by oversized single dose vials of cancer drugs

(2016) Peter B Bach et al.   BMJ-British Medical Journal

The drug industry can help reduce cancer drug costs

(2016) Peter J Gilbar et al.   BMJ-British Medical Journal

Overspending driven by oversized single dose vials of cancer drugs

(2016) Peter B Bach et al.   BMJ-British Medical Journal

Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review

(2016) Karen Lien et al.   Journal of Oncology Practice

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival

(2015) Chul Kim et al.   JAMA Internal Medicine

Drug waste minimization as an effective strategy of cost-containment in Oncology

(2014) Gianpiero Fasola et al.   BMC HEALTH SERVICES RESEARCH

Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel

(2014) M. Alexander et al.   INTERNAL MEDICINE JOURNAL

A 2-year retrospective review of vial sharing options for the compounding of cytotoxics

(2014) Rufus SV Smith   European Journal of Hospital Pharmacy-Science and Practice

A review of the evidence for occupational exposure risks to novel anticancer agents – A focus on monoclonal antibodies

(2014) Julie King et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Potential cost savings associated with dose rounding antineoplastic monoclonal agents

(2014) Sarah M Francis et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Long-term physico-chemical stability of diluted trastuzumab

(2013) Muriel Paul et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Delivering High-Quality and Affordable Care Throughout the Cancer Care Continuum

(2013) Ya-Chen Tina Shih et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Drugs in the United States: Justum Pretium—The Just Price

(2013) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents

(2012) E Chatelut et al.   BRITISH JOURNAL OF CANCER

Long-term stability of diluted solutions of the monoclonal antibody rituximab

(2012) Muriel Paul et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

The High Cost of Cancer Drugs and What We Can Do About It

(2012) Mustaqeem Siddiqui et al.   MAYO CLINIC PROCEEDINGS

Projections of the Cost of Cancer Care in the United States: 2010-2020

(2011) A. B. Mariotto et al.   JNCI-Journal of the National Cancer Institute

Ideal Vial Size for Bortezomib: Real-World Data on Waste and Cost Reduction in Treatment of Multiple Myeloma in Brazil

(2011) Luciana Clark et al.   VALUE IN HEALTH

Dose rounding of chemotherapy in colorectal cancer: An analysis of clinician attitudes and the potential impact on treatment costs

(2010) Kathryn FIELD et al.   Asia-Pacific Journal of Clinical Oncology

Controlling the cost of innovative cancer therapeutics

(2009) Nafees N. Malik   Nature Reviews Clinical Oncology